PD-1 mRNA lipid‑nanoparticle vaccine for advanced liver cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase 1 dose‑finding trial of a PD‑1 mRNA vaccine formulated in lipid nanoparticles in adults with recurrent or metastatic hepatocellular carcinoma after failure of second‑line therapy. Participants receive either a low or high dose of the PD‑1 mRNA LNP vaccine and are monitored for safety, tolerability, immune responses, and early signs of tumor shrinkage per RECIST. Key enrollment requirements include measurable disease, ECOG 0–1, adequate organ function, and expected survival of at least three months. The trial is conducted at West China Hospital, Sichuan University, with serial clinical, laboratory, and imaging assessments to characterize adverse events and preliminary efficacy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Male or female patients: ≥18 years of age; ≤70 years of age;
2. Recurrent or metastatic hepatocellular carcinoma that has failed second-line standard therapy.
3. Patients with at least one target lesion with a measurable diameter according to the RECIST criteria (CT scan of tumor lesions with a long diameter of ≥10mm, CT scan of lymph node lesions with a short diameter of ≥10mm and a layer thickness of no more than 5mm);
4. ECOG physical condition score: 0 to 1;
5. Expected survival ≥ 3 months;
6. Good function of major organs, i.e., relevant examination indexes within 14 days prior to randomization meet the following requirements:

   * Routine blood tests: hemoglobin ≥80g/L (no blood transfusion within 14 days); neutrophil count \>1.5×109 /L; platelet count ≥80×109 /L;
   * Biochemical tests: total bilirubin ≤1.5 × ULN (upper limit of normal); blood alanine aminotransferase (ALT) or blood alanine transaminase (AST) ≤ 2.5 × ULN; if liver metastases, ALT or AST ≤ 5 × ULN; endogenous creatinine clearance ≥ 60 ml/min (Cockcroft-Gault formula);
   * cardiac Doppler ultrasound: left ventricular ejection fraction (LVEF) (LVEF) ≥50%.
7. Good compliance and family agreement to cooperate in receiving survival follow-up.

Exclusion Criteria:

1. Participation in a clinical trial of another drug within 4 weeks;
2. Patients with a prior history of other neoplasms, unless cervical cancer in situ, treated squamous skin cancer or epithelial tumor of the bladder or other malignancies that have undergone radical therapy (at least 5 years prior to enrollment);
3. Patients with uncontrolled cardiac clinical symptoms or disease, such as NYHA class 2 or higher heart failure, unstable angina pectoris , myocardial infarction within 1 year, clinically significant Supraventricular or ventricular arrhythmias requiring treatment or intervention.
4. For female subjects: women who are pregnant or breastfeeding.
5. Patients with active tuberculosis, bacterial or fungal infection (≥ grade 2 of NCI-CTCAE 5.0); HIV infection; active HBV infection; HCV infection.
6. Those with a history of psychotropic substance abuse that they are unable to abstain from or those with mental disorders;
7. Subjects with any active autoimmune disease or history of autoimmune disease (e.g., the following, but not limited to : uveitis, enteritis, pituitary gland inflammation, nephritis, hyperthyroidism, hypothyroidism; subjects with vitiligo or asthma that has resolved completely in childhood and does not require any intervention in adulthood may be enrolled; subjects with asthma requiring medical intervention with bronchodilators may not be enrolled).
8. Patients who have been inoculated with mRNA drugs.
9. Participation in clinical trials involving lipid nanoparticles, a component of the study vaccine.
10. Contraindications to intramuscular injection.
11. History of substance abuse or known medical, psychological or social conditions such as alcohol or drug abuse.
12. Known allergy, hypersensitivity or intolerance to the investigational vaccine (including any excipients). Previous history of severe allergy to any drug, food, or vaccination, such as anaphylaxis, allergic laryngeal edema, allergic dyspnea, anaphylactic purpura, thrombocytopenic purpura, localized anaphylactic necrotic reaction (Arthus reaction).
13. The female subject is planning to become pregnant or the male subject's partner is planning to become pregnant during the Screening Period and up to 12 months after the full course of drug administration.
14. In the judgment of the investigator, there is a serious concomitant disease that jeopardizes the patient's safety or interferes with the patient's ability to complete the study.

Where it's running

• Sichuan University West China Hospital
  Chengdu, Sichuan, China Recruiting
• West China Hospital, Sichuan University
  Chengdu, Sichuan, China Not yet recruiting

Study contacts

• Principal investigator: Xingchen Peng — West China Hospital
• Study coordinator: Xingchen Peng
• Email: pxx2014@163.com
• Phone: 18980606753

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Integrated genomic and clinical database for cancer biomarker discovery

  Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.

  Recruiting Samsung Medical Center · Seoul, Gang-Nam · NCT07911267

• BGB-B2033 vs Sorafenib or Lenvatinib for advanced liver cancer

  This study tests whether the investigational drug BGB-B2033 can help people with advanced hepatocellular carcinoma when given after prior PD-1/PD-L1 therapy, compared with the standard medicines sorafenib or lenvatinib.

  Recruiting at 2 sites Phase 3 BeOne Medicines · South Brisbane, Queensland and 1 other locations · NCT07836530

• Protoacoustic Imaging to See Radiation Delivery in Proton Therapy

  This study tests radioacoustic imaging with ultrasound to help doctors see where proton therapy is delivering radiation for liver and prostate cancer patients.

  Recruiting University of Oklahoma · Oklahoma City, Oklahoma · NCT07832617

• YMN-136 vaccine for advanced liver, biliary tract, and pancreatic cancers

  A first-in-human dose-escalation study tests whether the YMN-136 vaccine is safe and tolerable for adults with unresectable advanced liver, biliary tract, or pancreatic cancers who have progressed on standard therapies or cannot receive them.

  Recruiting Phase 1 West China Hospital · Chengdu, Sichuan · NCT07763301

• DRAGON: International registry for patients who had combined portal and hepatic vein embolization before liver surgery

  This registry collects data on patients who had PVE/HVE before liver resection to see if it helps liver regeneration and what factors relate to outcomes.

  Recruiting at 30 sites Maastricht University Medical Center · Chicago, Illinois and 30 other locations · NCT07717437

• Precision navigation to boost cancer screening participation in high-risk communities

  This study tests whether a personalized navigation program helps adults aged 45–74 in Chinese communities who are at high risk for several cancers to complete recommended free cancer screenings.

  Recruiting at 3 sites Hunan Cancer Hospital · Huaihua, Hunan and 2 other locations · NCT07676383

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.